BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35428760)

  • 21. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Shen T; Dong B; Meng Y; Moore DD; Yang F
    Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells.
    Nagandla H; Robertson MJ; Putluri V; Putluri N; Coarfa C; Weigel NL
    Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33300995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
    Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
    Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
    Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 36. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
    Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.
    Chellini L; Pieraccioli M; Sette C; Paronetto MP
    J Exp Clin Cancer Res; 2022 May; 41(1):178. PubMed ID: 35590370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.
    Xu Y; Mu J; Zhou Z; Leng Y; Yu Y; Song X; Liu A; Zhu H; Li J; Wang D
    Stem Cell Res Ther; 2022 Jul; 13(1):299. PubMed ID: 35841025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
    Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
    Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.